Tarsus Acquisition Target Alkeus Announces JAMA Ophthalmology Publication Of TEASE-1 Data Showing Gildeuretinol Cut Retinal Lesion Growth Rate 21.6% vs. Untreated In 50-Patient Stargardt Disease Trial

Loading news article.

Tarsus Acquisition Target Alkeus Announces JAMA Ophthalmology Publication Of TEASE-1 Data Showing Gildeuretinol Cut Retinal Lesion Growth Rate 21.6% vs. Untreated In 50-Patient Stargardt Disease Trial | WAPE

Tarsus Acquisition Target Alkeus Announces JAMA Ophthalmology Publication Of TEASE-1 Data Showing Gildeuretinol Cut Retinal Lesion Growth Rate 21.6% vs. Untreated In 50-Patient Stargardt Disease Trial

Article summary

Related companies

Comments —